Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000837 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
- 20
- Study locations
NCT00000837 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 127 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT00000837, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if it is safe to give Varivax to HIV-positive children and whether it protects children from infection. Varivax is a vaccine against varicella zoster virus (VZV), the virus that causes chickenpox (varicella) and shingles (zoster). VZV can cause many serious complications in HIV-infected children. Varivax is a VZV vaccine that has been approved for use in healthy children. More research is needed to find out how this vaccine will affect HIV-infected children.
Conditions Studied
Interventions
- BIOLOGICAL Varicella Virus Vaccine (Live)
Study Locations (20)
California
- Long Beach Memorial Med. Ctr., Miller Children's Hosp. - Long Beach
- Usc La Nichd Crs - Los Angeles
- UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS - Los Angeles
- Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab. - Oakland
- Children's Hosp. of Orange County - Orange
- UCSD Mother-Child-Adolescent Program CRS - San Diego
- Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases - Torrance
Massachusetts
- HMS - Children's Hosp. Boston, Div. of Infectious Diseases - Boston
- BMC, Div. of Ped Infectious Diseases - Boston
- Baystate Health, Baystate Med. Ctr. - Springfield
Colorado
- Univ. of Colorado Denver NICHD CRS - Aurora
- The Children's Hosp. (Univ. of Colorado, Denver) P7001 CRS - Aurora
Maryland
- Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases - Baltimore
- Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology - Baltimore
New York
- Nyu Ny Nichd Crs - New York
- Metropolitan Hosp. Ctr. - New York
Connecticut
- Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease - New Haven
Florida
- South Florida CDTC Ft Lauderdale NICHD CRS - Fort Lauderdale
Illinois
- Chicago Children's CRS - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000837
The ClinicalTrials.gov registry entry for NCT00000837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (72% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Varicella Virus Vaccine (Live) is the first listed.
NCT00000837 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Massachusetts, Colorado.
Frequently Asked Questions
What is clinical trial NCT00000837 about?
NCT00000837 is a clinical study titled "A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children". The purpose of this study is to see if it is safe to give Varivax to HIV-positive children and whether it protects children from infection. Varivax is a vaccine against varicella zoster virus (VZV), the virus that causes chickenpox (varicella) and shingles (zoster). VZV can cause many serious compl...
What is the current status of trial NCT00000837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. Estimated completion is 2005-11.
What conditions does trial NCT00000837 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000837?
The interventions under investigation include: Varicella Virus Vaccine (Live) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00000837?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000837 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.